Abiopharma

🔍 Doyle Robin Ann (Executive)

Company: National Bank Holdings Corp (NBHC)

Report Date: 2026-05-06

Detailed Transactions and Holdings:

• Sold 663 shares of Common Stock at $42.96 per share (Direct)
  Date: 2026-05-06 | Code: F | equity_swap_involved: 0 | shares_owned_after: 4,567.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 3,153 shares of Common Stock (Direct)
  Date: 2026-05-07 | Code: A | equity_swap_involved: 0 | shares_owned_after: 7,720.00 | transaction_form_type: 4 | Footnotes: F2, F3

Footnotes:

• F1: Represents shares withheld for payment of tax liability upon vesting of the remainder of the restricted stock award granted to the reporting person on 04/30/2025.
• F2: This transaction represents a grant of restricted stock by the Issuer. Therefore, no consideration other than the value of services rendered was paid.
• F3: Total includes 3,153 unvested shares of restricted stock awarded under the National Bank Holdings Corporation 2023 Omnibus Incentive Plan, as amended and restated May 7, 2026, that will vest in two equal installments on (i) the 180th day following the date of grant and (ii) the day before the registrant's 2027 Annual Meeting of Shareholders, subject to continued service through the date of vesting.